Mylan Gets Approvals for Generic Versions of Hyzaar and Cozaar

Mylan Inc. announced that its subsidiary Mylan Pharmaceuticals Inc. received final approvals from the FDA for its Abbreviated New Drug Applications for the generic versions of Hyzaar Tablets, 50 mg/12.5 mg and 100 mg/25 mg, and Cozaar Tablets, 25 mg, 50 mg and 100 mg, both anti-hypertensives.
StreetInsider